AMGN241129P332500
- 0.00
- 0.000.00%
Amgen Newsroom
AMGN Stock Down Despite Strong Data From Obesity Drug Study
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Daily short sale tracking: GameStop's short volume increased by 1 million, with a short sale ratio of 12%
GameStop(GME.US) ranked top of the list had the largest change in short volume (1.49 million shares), and the short volume ratio of SLM Corp(SLM.US) reached 39.37%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
Today's Analyst Rating | Amgen Price Target Raised to $305 by Deutsche Bank, Applovin Price Target Raised to $400 by Jefferies
Nov 27, Wall Street analysts have updated their stock ratings today including $Amgen(AMGN.US)$ and $Applovin(APP.US)$.
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $305 to $380
Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete With Blockbuster Tirzepatide, Truist Says
Amgen's Stock Closes off Lows to Avoid Worst Day in 24 Years as Weight-loss-drug Data Underwhelms
Truist Financial Sticks to Their Hold Rating for Amgen (AMGN)
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Express News | Amgen Shares Down 1.6% Premarket ; at Least Two Brokerages Cut PT Following Mid-Stage Data for Weight-Loss Drug
Deutsche Bank Adjusts Price Target on Amgen to $285 From $305, Maintains Hold Rating
Express News | Amgen Inc : RBC Cuts Target Price to $330 From $360
US stocks unusual movement | Amgen continued to fall by more than 2.6% before the market opened, announcing that the weight loss drug trial effect is comparable to eli lilly and co's Zepbound but with more side effects.
Glonghui, November 27 - Amgen (AMGN.US) continued to decline more than 2.6% in pre-market trading, reporting $272.64. The stock fell 4.76% on Tuesday. In terms of news, Amgen announced on Tuesday that in a year-long trial, non-diabetic patients taking the weight loss drug MariTide once a month or less could lose up to 20% of their weight. Analysts pointed out that this is comparable to the effects of Eli Lilly and Co's Zepbound at its highest dose. However, data shows that the side effects of MariTide are greater than those of Zepbound, with about 11% of patients dropping out due to side effects.
Transaction volume TOP 20 | Bitcoin falls below 0.091 million dollars, microstrategy drops over 12%; eli lilly and co rises over 4%, the Biden administration plans to include weight loss drugs in the health insurance subsidy program.
On Tuesday, the stock trading volume leader was nvidia, which rose by 0.66% with a trading volume of 25.738 billion USD. nvidia announced on Monday the launch of its music-generating AI model, Fugatto, claiming it to be the "most flexible sound machine in the world," capable of precisely controlling sound generation. nvidia stated that this tool is like a "swiss army knife" for the sound field, being able to create music, modify sounds, and flexibly mix various music, vocals, and sound effects, even generating unprecedented sounds. The second place went to Tesla, which fell by 0.11% with a trading volume of 20.929 billion USD. ubs group published a bearish research report on Tesla. The institutions stated,
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Amgen Options Spot-On: On November 26th, 133.57K Contracts Were Traded, With 212.37K Open Interest
On November 26th ET, $Amgen(AMGN.US)$ had active options trading, with a total trading volume of 133.57K options for the day, of which put options accounted for 52.7% of the total transactions, and